SNYNF Quote, Financials, Valuation and Earnings

Moderna has a net margin of 17.65% compared to Sanofi SA's net margin of -907.48%. Sanofi SA's return on equity of 8.47% beat Moderna's return on equity of -29.23%.

Sanofi SA has a consensus price target of --, signalling upside risk potential of 33.68%. On the other hand Moderna has an analysts' consensus of $47.59 which suggests that it could grow by 48.44%. Given that Moderna has higher upside potential than Sanofi SA, analysts believe Moderna is more attractive than Sanofi SA.

Sanofi SA has a beta of 0.297, which suggesting that the stock is 70.34% less volatile than S&P 500. In comparison Moderna has a beta of 1.845, suggesting its more volatile than the S&P 500 by 84.505%.

Sanofi SA has a quarterly dividend of $4.40 per share corresponding to a yield of 4.59%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanofi SA pays 84.6% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend. Sanofi SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sanofi SA quarterly revenues are $11.2B, which are larger than Moderna quarterly revenues of $107M. Sanofi SA's net income of $2B is higher than Moderna's net income of -$971M. Notably, Sanofi SA's price-to-earnings ratio is 17.10x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi SA is 2.46x versus 3.97x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Novavax has a net margin of 17.65% compared to Sanofi SA's net margin of 82.81%. Sanofi SA's return on equity of 8.47% beat Novavax's return on equity of --.

Sanofi SA has a consensus price target of --, signalling upside risk potential of 33.68%. On the other hand Novavax has an analysts' consensus of $13.43 which suggests that it could grow by 92.94%. Given that Novavax has higher upside potential than Sanofi SA, analysts believe Novavax is more attractive than Sanofi SA.

Sanofi SA has a beta of 0.297, which suggesting that the stock is 70.34% less volatile than S&P 500. In comparison Novavax has a beta of 2.691, suggesting its more volatile than the S&P 500 by 169.079%.

Sanofi SA has a quarterly dividend of $4.40 per share corresponding to a yield of 4.59%. Novavax offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanofi SA pays 84.6% of its earnings as a dividend. Novavax pays out -- of its earnings as a dividend. Sanofi SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sanofi SA quarterly revenues are $11.2B, which are larger than Novavax quarterly revenues of $626.3M. Sanofi SA's net income of $2B is higher than Novavax's net income of $518.6M. Notably, Sanofi SA's price-to-earnings ratio is 17.10x while Novavax's PE ratio is 2.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi SA is 2.46x versus 0.95x for Novavax. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of 17.65% compared to Sanofi SA's net margin of 21.63%. Sanofi SA's return on equity of 8.47% beat Pfizer's return on equity of 8.72%.

Sanofi SA has a consensus price target of --, signalling upside risk potential of 33.68%. On the other hand Pfizer has an analysts' consensus of $29.23 which suggests that it could grow by 18.77%. Given that Sanofi SA has higher upside potential than Pfizer, analysts believe Sanofi SA is more attractive than Pfizer.

Sanofi SA has a beta of 0.297, which suggesting that the stock is 70.34% less volatile than S&P 500. In comparison Pfizer has a beta of 0.582, suggesting its less volatile than the S&P 500 by 41.783%.

Sanofi SA has a quarterly dividend of $4.40 per share corresponding to a yield of 4.59%. Pfizer offers a yield of 6.91% to investors and pays a quarterly dividend of $0.43 per share. Sanofi SA pays 84.6% of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend. Sanofi SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Pfizer's is not.

Sanofi SA quarterly revenues are $11.2B, which are smaller than Pfizer quarterly revenues of $13.7B. Sanofi SA's net income of $2B is lower than Pfizer's net income of $3B. Notably, Sanofi SA's price-to-earnings ratio is 17.10x while Pfizer's PE ratio is 17.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi SA is 2.46x versus 2.25x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.